摘要: Recently studies in selected tumors suggested that BRAF mutation may associates with survival benefit from immune checkpoint inhibitor (ICI) therapy. To broadly investigate this association at a pan-cancer level, we analyzed two independent ICI treatment cohorts (MSKCC: n = 1630, and Dana-Farber: n = 249). BRAF-mutant patients exhibit better overall survival in the MSKCC cohort (Hazard ratio [HR] = 0.55, 95% confidence interval [CI]: 0.43-0.72; P <.001) and the result is validated by the Dana-Farber cohort (HR = 0.68, 95% CI: 0.46-0.99; P = .045). A multivariate analysis adjusting tumor mutational burden, mismatch repair status, cancer type, age and sex confirmed the results (adjusted HR = 0.58, 95% CI = 0.43-0.78; P < .001). Immunogenomic features analysis of TCGA dataset indicated that patients may respond to immunotherapy in various mechanisms. This finding substantially improve the therapeutic prospects for a sizeable fraction of patients who benefit from immunotherapy.
-
来自:
葛维挺
-
分类:
医学、药学
>>
临床医学
-
引用:
ChinaXiv:202007.00041
(或此版本
ChinaXiv:202007.00041V1)
doi:10.12074/202007.00041
CSTR:32003.36.ChinaXiv.202007.00041.V1
- 推荐引用方式:
Ge, Weiting,Cai, Wen, Wu, Dehao,Hu, Wangxiong,Han, Weidong,Zheng, Shu,Hu, hanguang.(2020).BRAF mutation predicts survival after immunotherapy across multiple cancer types.中国科学院科技论文预发布平台.[ChinaXiv:202007.00041]
(点此复制)